This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 25/11/2343    most recent 01.ATV.0000184779.01822.9dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Granada, J. F. Articles by Durante, W. Search for Related Content PubMed PubMed Citation Articles by Granada, J. F. Articles by Durante, W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Hazardous Substances DB MITOMYCIN C Related Collections Restenosis Smooth muscle proliferation and differentiation

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2343.)
© 2005 American Heart Association, Inc.

Vascular Biology

Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries

Juan F. Granada; Diana Ensenat; Amit N. Keswani; Grzegorz L. Kaluza; Albert E. Raizner; Xiao-ming Liu; Kelly J. Peyton; Mohammed A. Azam; Hong Wang; William Durante

From The Methodist Research Institute (J.F.G., G.L.K., A.E.R.), Houston, Tex; Michael E. DeBakey VA Medical Center (D.E., A.N.K., X.L., K.J.P., M.A.A., H.W., W.D.) and the Departments of Medicine (D.E., A.N.K., X.L., K.J.P., M.A.A., H.W., W.D.) and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex.

Correspondence to William Durante, PhD, Michael E. DeBakey VA Medical Center, Bldg 109, Rm 130, 2002 Holcombe Blvd, Houston, TX 77030. E-mail wdurante{at}bcm.tmc.edu

Objective— Mitomycin C (MMc) is an antibiotic that exerts a potent antiproliferative effect in tumor cells. Because the proliferation of vascular smooth muscle cells (VSMCs) plays a prominent role in the development of restenosis after percutaneous coronary interventions, the present study examined the effect of MMc on VSMC proliferation and on neointima formation after arterial balloon injury.

Methods and Results— Treatment of cultured rat aortic VSMCs with MMc (1 nmol to 30 µmol/L) inhibited VSMC proliferation in a concentration-dependent manner. Whereas high concentrations of MMc (1 to 30 µmol/L) induced VSMC apoptosis, as reflected by DNA laddering and caspase-3 activation, lower concentrations of MMc (1 to 300 nmol/L) directly inhibited VSMC growth by arresting cells in the G₂/M phase of the cell cycle. The antiproliferative action of MMc was associated with a selective increase in the expression of the cyclin-dependent kinase inhibitor p21, and with a decrease in cyclin B1-cyclin-dependent kinase-1 complex activity. Finally, the local perivascular delivery of MMc immediately after balloon injury of rat carotid arteries induced p21 expression and markedly attenuated neointima formation.

Conclusion— These studies demonstrate that MMc exerts a potent inhibitory effect on VSMC proliferation and neointima formation after arterial injury. MMc represents a potentially new therapeutic agent in treating and preventing vasculoproliferative disease.

We examined the effect of mytomycin C (MMc) on VSMC proliferation. MMc inhibited the growth of cultured VSMCs and neointima formation after rat carotid artery balloon injury, and this was associated with increased p21 expression. MMc represents a potentially new therapeutic agent in preventing vasculoproliferative disorders.

Key Words: angioplasty • arteries • mitomycin C • restenosis • smooth muscle cells

This article has been cited by other articles:

				X.-m. Liu, M. A. Azam, K. J. Peyton, D. Ensenat, A. N. Keswani, H. Wang, and W. Durante Butylated hydroxyanisole stimulates heme oxygenase-1 gene expression and inhibits neointima formation in rat arteries Cardiovasc Res, April 1, 2007; 74(1): 169 - 179. [Abstract] [Full Text] [PDF]

				S.-L. Wang, J.-F. Han, X.-Y. He, X.-R. Wang, and J.-Y. Hong Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity Drug Metab. Dispos., January 1, 2007; 35(1): 176 - 179. [Abstract] [Full Text] [PDF]